The company is in early commercialization phase with Q1 2026 revenue of $0.15 million, up from $0.05 million a year earlier, but remains unprofitable. As of March 31, 2026, cash totaled $8.2 million, down from $11.9 million at year-end, as the company invests in R&D and expands regulatory certifications globally.
Cyborg Score Rationale
The company reported a net loss of $9.1 million in Q1 2026 despite revenue growth, with limited commercial traction and declining cash reserves. The company is pre-profitability with significant burn rate and regulatory execution risk.
Top Insights
Q1 2026 revenue tripled year-over-year to $0.15 million, showing early traction but commercial scale remains minimal
R&D expenses increased to $5.9 million in Q1 2026, primarily due to upper respiratory test clinical studies
Management highlighted regulatory progress including an Indian CDSCO license and ISO 13485 certification for the CoSara PCR platform
The company advanced PCR assay development strategy for Bundibugyo virus Ebola outbreak through joint venture CoSara Diagnostics
Named Competitors
Cepheid GeneXpert — Leading point-of-care molecular diagnostics platform